Harrison SA, et al. - The safety and efficacy of NGM282, an engineered FGF19 analogue (a hormone that regulated bile acid synthesis and glucose homoeostasis) were examined by the authors for the treatment of non-alcoholic steatohepatitis. Findings unveiled rapid and significant reductions in liver fat content through NGM282. It displayed an acceptable safety profile in patients with non-alcoholic steatohepatitis.